HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients

Autor: Monique C. Minnema, Kazem Nasserinejad, Ute Hegenbart, Paula F. Ypma, Ka Lung Wu, Marie Jose Kersten, Sandra Croockewit, Sonja Zweegman, Lidwine Tick, Annemiek Broijl, Harry Koene, Gerard M. J. Bos, Pieter Sonneveld, Stefan O. Schönland

Publikováno v: eJHaem, Vol 5, Iss 4, Pp 815-819 (2024)

Abstract The HOVON 104 studied bortezomib‐dexamethasone induction therapy and autologous stem cell transplantation in 50 patients, of whom 35 received an autologous stem cell transplantation (ASCT). We demonstrate a 5‐year overall survival (OS) o

Externí odkaz: https://doaj.org/article/601abdedab4a41ad8368ea73a9b0936d

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Autor: Beckers, M. M. J., Bekker, A., Bellido, M., de Boer, F., Broers, R., Chamuleau, M., Croockewit, A. J., Dompeling, E. C., Eefting, M., van Gelder, M., Hoogendoorn, M., Houtenbos, I., Doorduijn, J. K., Droogendijk, J., van der Griend, R., de Heer, K., Henkens, C. M. A., Idink, C. A. M., Issa, D. E., van Kampen, R., Kater, A. P., Kersting, S., van der Klift, M., Laterveer, L., Levenga, H., Levin, M-D., Mous, R., Nijland, M., Nijziel, M., van Norden, Y., Posthuma, E. F. M., te Raa, G. D., Raymakers, R. A. P., Regelink, J. C., Sandberg, Y., Schaafsma, M. R., Silbermann, M. H., van der Spek, A. C., van der Straaten, H. M., Tanis, B., Terpstra, W. E., Tick, L. W., Tonino, S. H., Veelken, J. H., Velders, G. A., Vlasveld, L., Visser, H. P. J., Vos, J. M. I., Wittebol, S., van Zaanen, H. C. T., van der Straten, Lina, Stege, Claudia A. M., Kersting, Sabina, Nasserinejad, Kazem, Dubois, Julie, Dobber, Johan A., Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie F., Evers, Ludo M., de Boer, Fransien, Koene, Harry R., Schreurs, John, van der Klift, Marjolein, Velders, Gerjo A., van der Spek, Ellen, van der Straaten, Hanneke M., Hoogendoorn, Mels, van Gelder, Michel, Posthuma, Eduardus F. M., Visser, Hein P. J., Houtenbos, Ilse, Idink, Cecile A. M., Issa, Djamila E., Dompeling, Ellen C., van Zaanen, Henk C. T., Veelken, J. Hendrik, Levenga, Henriette, Tick, Lidwine W., Terpstra, Wim E., Tonino, Sanne H., Westerweel, Peter E., Langerak, Anton W., Kater, Arnon P., Levin, Mark-David

Publikováno v: In Blood 28 September 2023 142(13):1131-1142

Exploring the Needs and Requirements of Informal Caregivers of Older Adults With Cognitive Impairment From Sensor-Based Care Solutions: Multimethod Study

Autor: Nikita Sharma, Louise M A Braakman-Jansen, Harri Oinas-Kukkonen, Jan Hendrik Croockewit, JEWC van Gemert-Pijnen

Publikováno v: JMIR Aging, Vol 6, p e49319 (2023)

BackgroundWith the increase in the older adult population, sensor-based care solutions that can monitor the deviations in physical, emotional, and physiological activities in real-time from a distance are demanded for prolonging the stay of community

Externí odkaz: https://doaj.org/article/c3b02e50993d4d7c9fae0385e7ee0931

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Autor: Pieter Sonneveld, Sonja Zweegman, Michele Cavo, Kazem Nasserinejad, Annemiek Broijl, Rosella Troia, Ludek Pour, Sandra Croockewit, Paolo Corradini, Francesca Patriarca, Kalung Wu, Jolanda Droogendijk, Gerard Bos, Roman Hajek, Maria Teresa Petrucci, Paula Ypma, Nicholas Zojer, Monique C. Minnema, Mario Boccadoro

Publikováno v: HemaSphere, Vol 6, Iss 10, p e786 (2022)

This phase 2 trial investigated reinduction with carfilzomib, pomalidomide, and dexamethasone (KPd) and continuous pomalidomide/dexamethasone in patients at first progression during lenalidomide maintenance. The second objective was to evaluate high-

Externí odkaz: https://doaj.org/article/98b6b44e179b444cb4be980901930363

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Autor: Cavo, Michele ^*, Gay, Francesca, Beksac, Meral, Pantani, Lucia, Petrucci, Maria Teresa, Dimopoulos, Meletios A, Dozza, Luca, van der Holt, Bronno, Zweegman, Sonja, Oliva, Stefania, van der Velden, Vincent H J, Zamagni, Elena, Palumbo, Giuseppe A, Patriarca, Francesca, Montefusco, Vittorio, Galli, Monica, Maisnar, Vladimir, Gamberi, Barbara, Hansson, Markus, Belotti, Angelo, Pour, Ludek, Ypma, Paula, Grasso, Mariella, Croockewit, Alexsandra, Ballanti, Stelvio, Offidani, Massimo, Vincelli, Iolanda D, Zambello, Renato, Liberati, Anna Marina, Andersen, Niels Frost, Broijl, Annemiek, Troia, Rossella, Pascarella, Anna, Benevolo, Giulia, Levin, Mark-David, Bos, Gerard, Ludwig, Heinz, Aquino, Sara, Morelli, Anna Maria, Wu, Ka Lung, Boersma, Rinske, Hajek, Roman, Durian, Marc, von dem Borne, Peter A, Caravita di Toritto, Tommaso, Zander, Thilo, Driessen, Christoph, Specchia, Giorgina, Waage, Anders, Gimsing, Peter, Mellqvist, Ulf-Henrik, van Marwijk Kooy, Marinus, Minnema, Monique, Mandigers, Caroline, Cafro, Anna Maria, Palmas, Angelo, Carvalho, Susanna, Spencer, Andrew, Boccadoro, Mario, Sonneveld, Pieter

Publikováno v: In The Lancet Haematology June 2020 7(6):e456-e468